Marianne Martinello1, Behzad Hajarizadeh2, Jason Grebely2, Gregory J Dore2,3, Gail V Matthews2,3. 1. Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, Wallace Wurth Building, Sydney, NSW, 2052, Australia. mmartinello@kirby.unsw.edu.au. 2. Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, Wallace Wurth Building, Sydney, NSW, 2052, Australia. 3. St Vincent's Hospital, Sydney, NSW, Australia.
Abstract
PURPOSE OF REVIEW: Highly effective, well-tolerated interferon-free direct-acting antivirals (DAA) have revolutionised hepatitis C virus (HCV) therapeutics, with the opportunity for broad treatment scale-up among marginalised or "high-risk" populations, including people who inject drugs (PWID) and people with HIV/HCV coinfection. RECENT FINDINGS: Concern that HCV reinfection may compromise HCV treatment outcomes is sometimes cited as a reason for not offering treatment to current and former PWID. However, the incidence of reinfection following interferon-based treatment for chronic HCV is low among PWID. Reinfection rates in HIV-positive men-who-have-sex-with-men (MSM) are varied, with high incidence reported in some cohorts. Mathematical modelling suggests that substantial reductions in HCV incidence and prevalence could be achieved with targeted DAA therapy among those at the highest risk of ongoing transmission. This review will summarise the recent literature on DAA efficacy in PWID and people with HIV/HCV coinfection, discuss the individual- and population-level impact of DAA treatment scale-up and reinfection, and highlight ongoing and future research questions in expanding HCV care and treatment to those populations at high risk of ongoing HCV transmission.
PURPOSE OF REVIEW: Highly effective, well-tolerated interferon-free direct-acting antivirals (DAA) have revolutionised hepatitis C virus (HCV) therapeutics, with the opportunity for broad treatment scale-up among marginalised or "high-risk" populations, including people who inject drugs (PWID) and people with HIV/HCV coinfection. RECENT FINDINGS: Concern that HCV reinfection may compromise HCV treatment outcomes is sometimes cited as a reason for not offering treatment to current and former PWID. However, the incidence of reinfection following interferon-based treatment for chronic HCV is low among PWID. Reinfection rates in HIV-positive men-who-have-sex-with-men (MSM) are varied, with high incidence reported in some cohorts. Mathematical modelling suggests that substantial reductions in HCV incidence and prevalence could be achieved with targeted DAA therapy among those at the highest risk of ongoing transmission. This review will summarise the recent literature on DAA efficacy in PWID and people with HIV/HCV coinfection, discuss the individual- and population-level impact of DAA treatment scale-up and reinfection, and highlight ongoing and future research questions in expanding HCV care and treatment to those populations at high risk of ongoing HCV transmission.
Authors: Edward J Gane; Christian Schwabe; Robert H Hyland; Yin Yang; Evguenia Svarovskaia; Luisa M Stamm; Diana M Brainard; John G McHutchison; Catherine A Stedman Journal: Gastroenterology Date: 2016-05-27 Impact factor: 22.682
Authors: Jason Grebely; Gregory J Dore; Stefan Zeuzem; Richard J Aspinall; Raymond Fox; Lingling Han; John McNally; Anu Osinusi; Diana M Brainard; G Mani Subramanian; Macky Natha; Graham R Foster; Alessandra Mangia; Mark Sulkowski; Jordan J Feld Journal: Clin Infect Dis Date: 2016-08-23 Impact factor: 9.079
Authors: Maryam Alavi; Tim Spelman; Gail V Matthews; Paul S Haber; Carolyn Day; Ingrid van Beek; Nick Walsh; Barbara Yeung; Julie Bruneau; Kathy Petoumenos; Kate Dolan; John M Kaldor; Gregory J Dore; Margaret Hellard; Jason Grebely Journal: Int J Drug Policy Date: 2015-05-21
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272
Authors: Amanda Weir; Allan McLeod; Hamish Innes; Heather Valerio; Esther J Aspinall; David J Goldberg; Stephen T Barclay; John F Dillon; Ray Fox; Andrew Fraser; Peter C Hayes; Nicholas Kennedy; Peter R Mills; Adrian J Stanley; Celia Aitken; Rory Gunson; Kate Templeton; Alison Hunt; Paul McIntyre; Sharon J Hutchinson Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492
Authors: Sarah Larney; Jason Grebely; Matthew Hickman; Daniela De Angelis; Gregory J Dore; Louisa Degenhardt Journal: Int J Drug Policy Date: 2015-07-26
Authors: Meredith E Clement; Lauren F Collins; Julius M Wilder; Michael Mugavero; Taryn Barker; Susanna Naggie Journal: Infect Dis Clin North Am Date: 2018-06 Impact factor: 5.982
Authors: Alexander P Underwood; Melanie R Walker; Nicholas A Brasher; Auda A Eltahla; Lisa Maher; Fabio Luciani; Andrew R Lloyd; Rowena A Bull Journal: Viruses Date: 2018-11-21 Impact factor: 5.048